BR112018068512A2 - métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 - Google Patents

métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3

Info

Publication number
BR112018068512A2
BR112018068512A2 BR112018068512A BR112018068512A BR112018068512A2 BR 112018068512 A2 BR112018068512 A2 BR 112018068512A2 BR 112018068512 A BR112018068512 A BR 112018068512A BR 112018068512 A BR112018068512 A BR 112018068512A BR 112018068512 A2 BR112018068512 A2 BR 112018068512A2
Authority
BR
Brazil
Prior art keywords
her2
breast cancer
hrg
treating
methods
Prior art date
Application number
BR112018068512A
Other languages
English (en)
Inventor
Czibere Akos
J Finn Gregory
Zhang Hong
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of BR112018068512A2 publication Critical patent/BR112018068512A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Abstract

trata-se de composições e métodos para tratar câncer de mama er+, her2- hrg+ (por exemplo , câncer de mama er+, her2- metastático) em um paciente administrando-se ao paciente um anticorpo anti-erbb3 (por exemplo , seribantumabe ) , um inibidor de cdk4/6 (por exemplo , palbociclibe), e uma terapia de base endócrina (por exemplo, letrozol ou fulvestranto) de acordo com um regime de dosagem clínica particular (isto é, em uma quantidade de dose particular e de acordo com um programa de dosagem específico). são também fornecidos no presente documento composições e métodos para tratar câncer de mama er+, her2- hrg+ (por exemplo , câncer de mama er+, her2- metastático) em um paciente, administrando-se ao paciente um anticorpo anti-erbb3 (por exemplo , seribantumabe ) e um terapia de base endócrina (por exemplo, letrozol ou fulvestranto) de acordo com um regime de dosagem clínica particular (isto é, em uma quantidade de dose particular e de acordo com um programa de dosagem específico).
BR112018068512A 2016-03-15 2017-03-15 métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 BR112018068512A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662308783P 2016-03-15 2016-03-15
US201662356127P 2016-06-29 2016-06-29
US201662431242P 2016-12-07 2016-12-07
PCT/US2017/022517 WO2017160990A1 (en) 2016-03-15 2017-03-15 Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody

Publications (1)

Publication Number Publication Date
BR112018068512A2 true BR112018068512A2 (pt) 2019-01-22

Family

ID=58428399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068512A BR112018068512A2 (pt) 2016-03-15 2017-03-15 métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3

Country Status (12)

Country Link
US (1) US20190091227A1 (pt)
EP (1) EP3429623A1 (pt)
JP (1) JP2019508428A (pt)
KR (1) KR20180119570A (pt)
CN (1) CN109310754A (pt)
AU (1) AU2017235450A1 (pt)
BR (1) BR112018068512A2 (pt)
CA (1) CA3011949A1 (pt)
IL (1) IL260935A (pt)
MX (1) MX2018011054A (pt)
SG (1) SG11201806251WA (pt)
WO (1) WO2017160990A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
KR102173464B1 (ko) 2016-12-01 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
JP6952747B2 (ja) * 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
AU2020216444A1 (en) * 2019-01-31 2021-07-29 Ionis Pharmaceuticals, Inc. Modulators of YAP1 expression
US20220125777A1 (en) * 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
JP2022546471A (ja) * 2019-08-26 2022-11-04 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
US11918561B2 (en) 2020-05-12 2024-03-05 Genentech, Inc. Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN117412766A (zh) * 2021-03-11 2024-01-16 艾利维申肿瘤学公司 抗erbb3(her3)单克隆抗体治疗与神经调节蛋白1(nrg1)基因融合相关肿瘤的剂量和给药
WO2023107525A1 (en) * 2021-12-10 2023-06-15 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2023230288A1 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN115068613A (zh) * 2022-07-07 2022-09-20 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 泛tki在治疗hr阳性her2低表达乳腺癌的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
BR122014028365B8 (pt) * 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
ES2582386T3 (es) 2007-03-01 2016-09-12 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag Anti-HER3 antibodies and their applications
EA201201186A1 (ru) 2010-03-11 2013-11-29 Мерримак Фармасьютикалс, Инк. ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EA036314B1 (ru) 2010-08-20 2020-10-26 Новартис Аг Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
MX2013010379A (es) * 2011-03-11 2014-03-27 Merrimack Pharmaceuticals Inc Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
EA201490180A1 (ru) 2011-06-30 2014-08-29 Мерримак Фармасьютикалз, Инк. Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
AU2012294326A1 (en) 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
AU2013201584A1 (en) 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
PT3033086T (pt) * 2013-08-14 2021-12-15 Novartis Ag Terapia de combinação para o tratamento de cancro
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Also Published As

Publication number Publication date
US20190091227A1 (en) 2019-03-28
AU2017235450A1 (en) 2018-08-16
JP2019508428A (ja) 2019-03-28
KR20180119570A (ko) 2018-11-02
MX2018011054A (es) 2019-01-21
CA3011949A1 (en) 2017-09-21
WO2017160990A1 (en) 2017-09-21
CN109310754A (zh) 2019-02-05
IL260935A (en) 2018-10-31
SG11201806251WA (en) 2018-08-30
EP3429623A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112016007479A2 (pt) regimes de dosagem de imunoconjugado de anti-folr1
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112021008582A8 (pt) Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
BR112018010012A2 (pt) regimes de dosagem de melflufen para câncer
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
BR112017027378A2 (pt) linhagem atenuada de salmonella e composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]